These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 8748432

  • 1. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
    Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW, Pande AC.
    J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
    [Abstract] [Full Text] [Related]

  • 2. Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder.
    Sramek JJ, Costa JF, Adams JB, Macpherson A, Cutler NR.
    Anxiety; 1995 Dec; 1(5):242-3. PubMed ID: 9160582
    [No Abstract] [Full Text] [Related]

  • 3. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
    Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW.
    Biol Psychiatry; 1999 Sep 15; 46(6):860-2. PubMed ID: 10494457
    [Abstract] [Full Text] [Related]

  • 4. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov 15; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study.
    Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D.
    J Clin Psychiatry; 2002 Nov 15; 63(11):1020-7. PubMed ID: 12444816
    [Abstract] [Full Text] [Related]

  • 6. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
    Cutler NR, Sramek JJ, Macpherson AE, Doss MG, Benes CO, Howard SF.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul 15; 18(4):685-94. PubMed ID: 7938559
    [Abstract] [Full Text] [Related]

  • 7. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
    van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC.
    Psychopharmacology (Berl); 1997 Feb 15; 129(3):243-8. PubMed ID: 9084062
    [Abstract] [Full Text] [Related]

  • 8. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
    Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E.
    J Clin Psychopharmacol; 1993 Dec 15; 13(6):429-37. PubMed ID: 7907097
    [Abstract] [Full Text] [Related]

  • 9. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.
    Cowley DS, Adams JB, Pyke RE, Cook J, Zaccharias P, Wingerson D, Roy-Byrne PP.
    Biol Psychiatry; 1996 Sep 15; 40(6):550-2. PubMed ID: 8879478
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.
    JAMA; 2000 Jun 21; 283(23):3082-8. PubMed ID: 10865302
    [Abstract] [Full Text] [Related]

  • 11. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec 21; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 12. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
    Pollack MH, Tiller J, Xie F, Trivedi MH.
    J Clin Psychopharmacol; 2008 Jun 21; 28(3):308-16. PubMed ID: 18480688
    [Abstract] [Full Text] [Related]

  • 13. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC.
    Arch Gen Psychiatry; 2005 Sep 21; 62(9):1022-30. PubMed ID: 16143734
    [Abstract] [Full Text] [Related]

  • 14. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA.
    J Clin Psychiatry; 2002 Apr 21; 63(4):308-15. PubMed ID: 12000204
    [Abstract] [Full Text] [Related]

  • 15. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
    Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Donahue SR, Kauffman M, Iyer GR, Reinhard JF.
    J Clin Psychopharmacol; 2008 Apr 21; 28(2):235-9. PubMed ID: 18344738
    [Abstract] [Full Text] [Related]

  • 16. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
    Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T.
    J Affect Disord; 2009 Jun 21; 115(3):376-85. PubMed ID: 19042026
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR, DuPont RL, Hedges D, Haskins JT.
    J Clin Psychiatry; 1999 Aug 21; 60(8):528-35. PubMed ID: 10485635
    [Abstract] [Full Text] [Related]

  • 18. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR, Sramek JJ, Wardle TS, Hesselink JM, Roeschen JK.
    Psychopharmacol Bull; 1993 Aug 21; 29(2):303-8. PubMed ID: 7904761
    [Abstract] [Full Text] [Related]

  • 19. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
    Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matzura-Wolfe D, Lines C, Reines S.
    Biol Psychiatry; 1995 Apr 01; 37(7):462-6. PubMed ID: 7786960
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
    Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y.
    Hum Psychopharmacol; 2014 Jan 01; 29(1):64-72. PubMed ID: 24424707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.